Literature DB >> 12480690

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.

Dharminder Chauhan1, Guilan Li, Daniel Auclair, Teru Hideshima, Paul Richardson, Klaus Podar, Nicholas Mitsiades, Constantine Mitsiades, Cheng Li, Ryung Suk Kim, Nikhil Munshi, Lan Bo Chen, Wing Wong, Kenneth C Anderson.   

Abstract

Our previous study demonstrated that 2-methoxyestradiol (2ME2), an estrogen derivative, induces apoptosis in multiple myeloma (MM) cells; however, the related transcriptional events are unclear. In the present study, we used oligonucleotide microarrays to identify genes altered during 2ME2-induced apoptosis in MM cells. 2ME2 triggers an early transient induction of genes known to trigger cell death and repression of growth/survival-related genes. Many genes regulating cell defense/repair machinery also were transiently induced. Since 2ME2 also induces apoptosis in MM cells resistant to conventional therapies such as dexamethasone (Dex), we compared the gene profiles of 2ME2-treated and Dex-resistant MM cells. Our results suggest that 2ME2 overcomes Dex resistance by modulating genes that confer chemoresistance in MM cells. Microarray results were confirmed by Northern and Western blot analyses. A comparative analysis of selected genes from freshly isolated MM patient cells and 2ME2-treated MM.1S MM cells further provides an in vivo relevance of our in vitro studies. Collectively, these findings suggest genetic events mediating anti-MM activity of 2ME2, as well as mechanisms whereby 2ME2 overcomes Dex resistance in MM cells. These studies may therefore allow improved therapeutic use of 2ME2, based upon targeting genes that regulate MM cell growth and survival.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12480690     DOI: 10.1182/blood-2002-10-3146

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Candidate genes and mechanisms for 2-methoxyestradiol-mediated vasoprotection.

Authors:  Federica Barchiesi; Eliana Lucchinetti; Michael Zaugg; Omolara O Ogunshola; Matthew Wright; Markus Meyer; Marinella Rosselli; Sara Schaufelberger; Delbert G Gillespie; Edwin K Jackson; Raghvendra K Dubey
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

Review 2.  The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Authors:  Sarah K Johnson; Christoph J Heuck; Anthony P Albino; Pingping Qu; Qing Zhang; Bart Barlogie; John D Shaughnessy
Journal:  Int J Hematol       Date:  2011-10-15       Impact factor: 2.490

3.  Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.

Authors:  Arghya Ray; Yan Song; Ting Du; Dharminder Chauhan; Kenneth C Anderson
Journal:  Oncogene       Date:  2020-02-05       Impact factor: 9.867

4.  Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine.

Authors:  Sandhya K Nair; Arti Verma; T J Thomas; T C Chou; Michael A Gallo; Akira Shirahata; Thresia Thomas
Journal:  Cancer Lett       Date:  2006-12-20       Impact factor: 8.679

Review 5.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

6.  Changes in the gene expression pattern induced by 2-methoxyestradiol in the mouse uterus.

Authors:  Ramiro J Rincón-Rodríguez; María L Oróstica; Patricia Díaz; Patricia Reuquén; Hugo Cárdenas; Pedro A Orihuela
Journal:  Endocrine       Date:  2013-03-15       Impact factor: 3.633

7.  Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1.

Authors:  Teresa S Hawley; Irene Riz; Wenjing Yang; Yoshiyuki Wakabayashi; Louis Depalma; Young-Tae Chang; Weiqun Peng; Jun Zhu; Robert G Hawley
Journal:  Am J Hematol       Date:  2013-03-08       Impact factor: 10.047

Review 8.  Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.

Authors:  Karène Mahtouk; Dirk Hose; John De Vos; Jérôme Moreaux; Michel Jourdan; Jean François Rossi; Thierry Rème; Harmut Goldschmidt; Bernard Klein
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

Review 9.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

Review 10.  Bone marrow microenvironment and the identification of new targets for myeloma therapy.

Authors:  K Podar; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2008-10-09       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.